Order Form
Neurodegenerative Diseases

General Information

Patient

Surname: _____

First name: _____

Date of birth: _____

Sex: ❑ male ❑ female

Material

❑ Blood ____ ml (min. 3 ml EDTA-blood)

❑ Dried blood spot cards (at least 10 spots)

❑ DNA ____ µg (min. 5 µg DNA, concentr. ≥ 50 ng/µl) DNA-No.: _____

❑ Other specimen _____

External ID: _____

Date of sample collection: _____

Samples can be sent by mail in a cardboard box or air cushion envelope. Samples should not be exposed to direct sunlight. Dried blood spot cards can be ordered for free (info@cegat.com).

Sender / Clinic

Surname:

First name:

Institution:

Street:

Postcode/City:

Country:

Phone:

Email:

If applicable, please include a VAT number or a copy of your business registration certificate.

VAT: _____

Invoice

❑ to patient ❑ to sender / clinic

Declaration of consent

By signing this form, I declare that I have received comprehensive information about the genetic background related to the disease in question as well as the possibilities and limitations of molecular genetic testing. I understand that I have the right to withdraw my consent to genetic analyses.

I have been informed, and agree, that the data obtained in the analysis will be recorded, evaluated, or stored in an anonymized form in scientific databases, and further, in accordance with data protection and medical confidentiality, that the request, or parts thereof, may be transmitted to a specialized cooperating laboratory. I have been informed, and agree, that all data collected by CeGaT GmbH is electronically stored, processed, and used. I also consent to the data being transmitted electronically (e.g. by e-mail or fax).

If you do not check these boxes, your answer will be recorded as "No".

I consent to the storage of my genetic material for additional tests and/or quality control (for max. 10 years). ❑ Yes ❑ No

I consent to the storage of my test results beyond the timespan of 10 years (as required by German law). ❑ Yes ❑ No

I consent to the anonymous storage and use of surplus genetic material and/or test results for scientific research. ❑ Yes ❑ No

Genetic variation may sometimes be identified, which does not fit within the scope of the requested genetic analysis (so-called secondary findings report). The reporting of these variants is limited to pathogenic alterations within selected genes, for which a treatment or course of action exists for you or your family (according to the current guidelines of the American College of Medical Genetics and Genomics; ACMG SF V2.0; Kalia et al., 2017, PMID: 27854360). There is no claim of a comprehensive analysis of the genes included within the secondary findings report. An absence of secondary findings cannot be used to indicate a reduced disease risk.

With regard to secondary findings I would like:

❑ to be informed

❑ to NOT be informed

Please Note

Our panels are regularly updated to reflect current scientific research. It should therefore be recognized that there is the possibility that the list of genes on the order form may have changed slightly (genes added or removed) by the time the sample is analyzed in the laboratory. By signing this form, the patient accepts that the list of genes actually analyzed may be slightly different from what is currently listed. When NGS is utilized more than the requested genes are sequenced for each sample.

This declaration of consent can be completely or partially withdrawn at any time. I have had sufficient time to consider giving my consent.

_____ _____

Patient / Legal Guardian (Block letters) Doctor (Surname, First name)

X _____ **X** _____

Patient / Legal Guardian (Date, Signature) Doctor (Date, Signature)

Doctor's stamp / Barcode

Contact

To discuss the diagnostic strategy please do not hesitate to contact us.
Phone: +49 7071 565 44-55
Email: diagnostic-support@cegat.de

DAkkS Deutsche Akkreditierungsstelle D-ML-13206-01-00

CAP ACCREDITED COLLEGE of AMERICAN PATHOLOGISTS CLIA CERTIFIED ID: 99D2130225

CeGaT is accredited by DAkkS according to DIN EN ISO 15189:2014, by the College of American Pathologists (CAP) and CLIA.

Order Form
Neurodegenerative Diseases
Indication

Indication / Suspected Diagnosis:

Clinical Major Symptoms:

Preliminary genetic diagnostics:

Transplants (bone marrow, tissue, stem cells) ❑ No ❑ Yes, (please specify) _____

Please include a copy of all existing reports of your patient.

Pedigree

Consanguinity: ❑ Yes ❑ No Ethnic origin: _____

Family medical history

Are there other family members who currently have or have had the same or a similar disease as the patient?

❑ Yes ❑ No

If yes, please list the affected family members:

Name (not required)	Relationship to the patient (e.g. mother)	Age of onset	Diagnosis / Symptoms

Order Form
Neurodegenerative Diseases
Inquiry

The analysis is performed in a stepwise manner.
We will contact the referring physician in order to clarify analysis procedures.

Inquiry

All genes listed on this order form, and the entire mitochondrial genome, are sequenced in parallel. This allows you to select multiple gene sets, or choose individual genes in addition to your selected gene set. As there is no additional laboratory expenditure, there is only a moderate price increase due to the subsequent analysis and interpretation. We are happy to answer your questions or send you an individual quote. Please contact us at info@cegat.com.

❑ **Large Panel Diagnostic Option (351 Genes, NDD-D45)**

In addition to the full analysis of the requested gene set(s), we will expand the analysis to all pathogenic and likely pathogenic variants (ACMG class 4 and 5) in genes which are related to the indication described for the proband on the entire diagnostic panel (351 genes in total).

❑ **Parkinson's disease, autosomal dominant (5 Genes, NDD01)**
CHCHD2, GBA, LRRK2, SNCA, VPS35

❑ **Parkinson's disease, autosomal recessive (10 Genes, NDD02)**
ATP13A2, DNAJC6, FBXO7, PARK2 (PRKN), PARK7, PINK1, PLA2G6, SLC30A10, SYNJ1, VPS13C

❑ **Atypical Parkinson's disease (15 Genes, NDD03)**
ATP13A2, ATP1A3, DCTN1, DNAJC6, FBXO7, FTL, GCH1, GRN, MAPT, PLA2G6, RAB39B, SLC30A10, SPG11, SYNJ1, TH

❑ **Dystonia-Parkinsonism (11 Genes, NDD04)**
ATP1A3, DNAJC12, GCH1, PLA2G6, PRKRA, SLC30A10, SLC39A14, SLC6A3, SPR, TAF1, TH

❑ **Parkinson's disease (32 Genes, NDD05)**
ATP13A2, ATP1A3, C19ORF12, CHCHD2, DCTN1, DNAJC12, DNAJC6, FBXO7, FTL, GBA, GCH1, GRN, LRRK2, MAPT, PANK2, PARK2 (PRKN), PARK7, PINK1, PLA2G6, PRKRA, RAB39B, SLC30A10, SLC39A14, SLC6A3, SNCA, SPG11, SPR, SYNJ1, TAF1, TH, VPS13C, VPS35

❑ **Primary torsion dystonia (8 Genes, NDD06)**
ANO3, CIZ1, COL6A3, GNAL, HPCA, THAP1, TOR1A, TUBB4A

❑ **Dystonia Plus syndrome (13 Genes, NDD07)**
ATP1A3, BCAP31, COX20, FTL, GCH1, KIF1C, PRKRA, SGCE, SLC30A10, SPR, TAF1, TH, TUBB4A

❑ **Paroxysmal dyskinesia (11 Genes, NDD08)**
ADCY5, ATP1A3, CACNA1A, GCH1, KCNA1, KCNMA1, PARK2 (PRKN), PNKD, PRRT2, SCN8A, SLC2A1

❑ **Heredodegenerative syndromes (37 Genes, NDD09)**
ARSA, ATM, ATP13A2, ATP7B, AUH, C19ORF12, CLN3, CSF1R, CYP27A1, DCTN1, FBXO7, FTL, FUCA1, GCDH, HEPACAM, HEXA, HPRT1, HTT, MECP2, MLC1, NPC1, NPC2, NUP62, OPA3, PANK2, PARK2 (PRKN), PLA2G6, PLP1, SLC16A2, SLC19A3, SLC25A15, SLC30A10, SLC6A3, SMPD1, TAF1, VPS13A, WDR45

❑ **Dystonia (46 Genes, NDD10)**
ADAR, ADCY5, ANO3, ATM, ATP1A3, ATP7B, BCAP31, CACNA1A, CACNA1B, CIZ1, COL6A3, COX20, DDC, DNAJC12, FA2H, FTL, GCDH, GCH1, GNAL, HPCA, KCNA1, KCNMA1, KIF1C, KMT2B, MECR, PANK2, PARK2 (PRKN), PLA2G6, PNKD, PRKRA, PRRT2, SCN8A, SGCE, SLC19A3, SLC2A1, SLC30A10, SLC39A14, SLC6A3, SPR, TAF1, TH, THAP1, TOR1A, TUBB4A, VAC14, VPS13A

❑ **Neurodegeneration with brain iron accumulation (NBIA) (10 Genes, NDD11)**
ATP13A2, C19ORF12, COASY, CP, DCAF17, FA2H, FTL, PANK2, PLA2G6, WDR45

❑ **Neuroacanthocytosis (3 Genes, NDD12)**

❑ JPH3 repeat analysis

PANK2, VPS13A, XK

❑ **Choreatic movement disorders (7 Genes, NDD13)**

❑ HTT, JPH3 repeat analyses

ADCY5, ATM, FRRS1L, GNAO1, NKX2-1, PDE10A, PRNP, HTT

❑ **Ataxia, autosomal dominant (25 Genes, NDD25)**

❑ SCA1, SCA2, SCA3, SCA6, SCA7, SCA17 repeat analyses

AFG3L2, ATP1A3, CACNA1A, CACNA1G, CACNB4, CAMTA1, CCDC88C, EEF2, ELOVL4, ELOVL5, FGF14, ITPR1, KCNA1, KCNC3, KCND3, PDYN, PRKCG, SAMD9L, SLC1A3, SPG7, SPTBN2, TGM6, TMEM240, TTBK2, VAMP1

❑ **Ataxia, autosomal recessive (43 Genes, NDD26)**

❑ FXN repeat analysis

ADCK3 (COQ8A), AFG3L2, ANO10, APTX, ATCAY, ATM, ATP2B3, ATP8A2, CA8, CP, CWF19L1, FXN, GOSR2, GRID2, GRM1, HEXA, HEXB, KIAA0226 (RUBCN), KIF1C, MARS2, MRE11A (MRE11), NKX6-2, PLA2G6, PMPCA, PNKP, POLG, PRICKLE1, RNF216, SACS, SCYL1, SETX, SNX14, SPG7, SPTBN2, STUB1, SYNE1, SYT14, TDP1, TPP1, TTPA, VLDLR, WDR81, WWOX

❑ **Episodic ataxia (4 Genes, NDD30)**
CACNA1A, CACNB4, KCNA1, SLC1A3

❑ **Ataxia and differential diagnoses (101 Genes, NDD14)**

❑ SCA1, SCA2, SCA3, SCA6, SCA7, SCA17 repeat analyses

❑ FXN repeat analysis

ABCB7, ABHD12, ADCK3 (COQ8A), AFG3L2, ANO10, APTX, ARSA, ATCAY, ATM, ATP1A3, ATP2B3, ATP8A2, C10ORF2 (TWNK), CA8, CACNA1A, CACNA1G, CACNB4, CAMTA1, CAPN1, CCDC88C, CLCN2, CP, CWF19L1, CYP27A1, DARS2, DNAJC5, DNMT1, EEF2, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, ELOVL4, ELOVL5, FGF14, FLVCR1, FOLR1, FXN, GBA2, GFAP, GOSR2, GRID2, GRM1, HEXA, HEXB, ITPR1, KCNA1, KCNC3, KCND3, KCNJ10, KIAA0226 (RUBCN), KIF1C, MARS2, MRE11A (MRE11), MTTP, NKX2-1, NKX6-2, NPC1, NPC2, PAX6, PDYN, PEX7, PHYH, PLA2G6, PMPCA, PNKP, PNPLA6, POLG, POLR3A, PRICKLE1, PRKCG, PRRT2, RNF170, RNF216, SACS, SAMD9L, SCYL1, SETX, SIL1, SLC1A3, SLC2A1, SNX14, SPG7, SPTBN2, STUB1, SYNE1, SYT14, TDP1, TGM6, TMEM240, TPP1, TTBK2, TTC19, TTPA, VAMP1, VLDLR, VRK1, WDR81, WFS1, WWOX

❑ **Frontotemporal dementia (17 Genes, NDD15)**

❑ C9ORF72 repeat analysis

CHCHD10, CHMP2B, CSF1R, FUS, GRN, ITM2B, MAPT, NOTCH3, PRNP, PSEN1, PSEN2, SQSTM1, TARDBP, TBK1, TREM2, UBQLN2, VCP

❑ **Alzheimer's disease (4 Genes, NDD16)**

APOE, APP, PSEN1, PSEN2

❑ **Dementia (19 Genes, NDD17)**

❑ C9ORF72 repeat analysis

APOE, APP, CHCHD10, CHMP2B, CSF1R, FUS, GRN, ITM2B, MAPT, NOTCH3, PRNP, PSEN1, PSEN2, SQSTM1, TARDBP, TBK1, TREM2, UBQLN2, VCP

❑ **Amyotrophic lateral sclerosis (ALS) (23 Genes, NDD18)**

❑ C9ORF72 repeat analysis

ALS2, ANG, CHCHD10, CHMP2B, DCTN1, FIG4, FUS, HNRNPA1, KIF5A, MATR3, OPTN, PFN1, SETX, SIGMAR1, SOD1, SPG11, SQSTM1, TARDBP, TBK1, TUBA4A, UBQLN2, VAPB, VCP

Order Form

Neurodegenerative Diseases

Inquiry

- ❑ **Hereditary spastic paraplegia (HSP), autosomal dominant (12 Genes, NDD27)**
  ALDH18A1, ATL1, BSCL2, HSPD1, KIAA0196 (WASHC5), KIDINS220, KIF5A, NIPA1, REEP1, REEP2, RTN2, SPAST

- ❑ **Hereditary spastic paraplegia (HSP), autosomal recessive (32 Genes, NDD28)**
  ALDH18A1, ALS2, AP4B1, AP4E1, AP4M1, AP4S1, AP5Z1, ATP13A2, B4GALNT1, C12ORF65, CAPN1, CYP2U1, CYP7B1, DDHD1, DDHD2, ERLIN2, FA2H, GBA2, KIF1A, L1CAM, MAG, NT5C2, PLP1, PNPLA6, REEP2, SPG11, SPG20 (SPART), SPG21, SPG7, TECPR2, TFG, ZFYVE26

- ❑ **Hereditary spastic paraplegia (HSP) all (56 Genes, NDD20)**
  ADAR, AFG3L2, AIMP1, ALDH18A1, ALS2, AP4B1, AP4E1, AP4M1, AP4S1, AP5Z1, ATL1, ATP13A2, B4GALNT1, BSCL2, C12ORF65, CAPN1, CYP2U1, CYP7B1, DDHD1, DDHD2, DSTYK, ERLIN2, FA2H, GALC, GBA2, HSPD1, IFIH1, KIAA0196, KIDINS220, KIF1A, KIF1C, KIF5A, L1CAM, MAG, NIPA1, NKX6-2, NT5C2, PLA2G6, PLP1, PNPLA6, POLR3A, REEP1, REEP2, RNASEH2B, RTN2, SACS, SLC16A2, SPAST, SPG11, SPG20, SPG21, SPG7, TECPR2, TFG, TUBB4A, ZFYVE26

- ❑ **Neuronal ceroid lipofuscinosis (NCL) (13 Genes, NDD21)**
  ATP13A2, CLN3, CLN5, CLN6, CLN8, CTSD, CTSF, DNAJC5, GRN, KCTD7, MFSD8, PPT1, TPP1

- ❑ **Leukodystrophy and Leukoencephalopathy (78 Genes, NDD29)**
  AARS, AARS2, ABCD1, ACOX1, ADAR, AIMP1, ALDH3A2, APOA1BP (NAXE), ARSA, ASPA, BCAP31, C11ORF73 (HIKESHI), CLCN2, CSF1R, CTC1, CTSA, CYP27A1, DARS, DARS2, EARS2, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, FAM126A, FUCA1, GALC, GBE1, GCDH, GFAP, GJC2, HEPACAM, HSD17B4, HSPD1, HTRA1, IFIH1, L2HGDH, LMNB1, MLC1, NOTCH3, OBFC1 (STN1), PEX1, PEX10, PEX11B, PEX12, PEX13, PEX14, PEX16, PEX19, PEX2, PEX26, PEX3, PEX5, PEX6, PEX7, PLEKHG2, PLP1, POLR1C, POLR3A, POLR3B, PSAP, PYCR2, RARS, RNASEH2A, RNASEH2B, RNASEH2C, RNASET2, SAMHD1, SCP2, SLC16A2, SLC17A5, SNORD118, SOX10, SUMF1, TREX1, TUBB4A, VPS11

- ❑ **Leukodystrophy / Leukoencephalopathy and differential diagnoses (133 Genes, NDD22)**
  AARS, AARS2, ABCD1, ACOX1, ADAR, AIMP1, ALDH3A2, APOA1BP (NAXE), APOPT1, ARSA, ASPA, BCAP31, BOLA3, C11ORF73 (HIKESHI), CLCN2, COL4A1, COL4A2, CSF1R, CTC1, CTSA, CYP27A1, DARS, DARS2, EARS2, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, ERCC6, ERCC8, FA2H, FAM126A, FKRP, FKTN, FOLR1, FUCA1, GALC, GAN, GBE1, GCDH, GFAP, GJC2, GLA, GLB1, GLRX5, GMPPB, HEPACAM, HEXA, HSD17B4, HSPD1, HTRA1, IBA57, IDS, IFIH1, ISCA2, KCNT1, KIF5A, L2HGDH, LAMA2, LARGE (LARGE1), LMNB1, LYRM7, MCOLN1, MLC1, MTFMT, NDUFS1, NDUFV1, NEU1, NFU1, NKX6-2, NOTCH3, NPC1, NPC2, OBFC1 (STN1), OCLN, PC, PEX1, PEX10, PEX11B, PEX12, PEX13, PEX14, PEX16, PEX19, PEX2, PEX26, PEX3, PEX5, PEX6, PEX7, PHGDH, PLA2G6, PLAA, PLEKHG2, PLP1, POLG, POLR1C, POLR3A, POLR3B, POMGNT1, POMT1, POMT2, PPT1, PSAP, PSAT1, PYCR2, RARS, RNASEH2A, RNASEH2B, RNASEH2C, RNASET2, SAMHD1, SCP2, SDHA, SDHAF1, SLC16A2, SLC17A5, SLC1A4, SLC25A12, SNORD118, SOX10, SPTAN1, SUMF1, SURF1, TPP1, TREM2, TREX1, TUBB4A, TUFM, TYMP, TYROBP, VPS11

- ❑ **Cerebral small vessel disease (10 Genes, NDD23)**
  APP, COL4A1, COL4A2, CTSA, FOXC1, GLA, HTRA1, NOTCH3, SNORD118, TREX1

- ❑ **Basal ganglia calcification (20 Genes, NDD24)**
  ADAR, CA2, COL4A1, CTC1, ERCC6, ERCC8, GALC, IFIH1, OCLN, PDGFB, PDGFRB, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, SLC20A2, TREM2, TREX1, TYROBP, XPR1

Additional analyses

For further information and advice please do not hesitate to contact our Diagnostic Support team.

www.cegat.de/en/diagnostic-support · diagnostic-support@cegat.de · Phone +49 7071 565 44-55